Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 15/20 | 0.54 |
| ▸ | FLT3 | P36888 | 5/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NRAS | P01111 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376369 | 0.90 | IRAK4 (0.56) | IRAK4FLT3MAPK8MAPK9NRAS | |
| SCHEMBL10239904 | 0.90 | IRAK4 (0.56) | IRAK4FLT3MAPK8MAPK9NRAS | |
| SCHEMBL10239869 | 0.85 | IRAK4 (0.59) | IRAK4FLT3MAPK8MAPK9CDK2 | |
| SCHEMBL12553157 | 0.83 | IRAK4 (0.59) | IRAK4FLT3MAPK8MAPK9CDK2 | |
| SCHEMBL376798 | 0.83 | IRAK4 (0.59) | IRAK4FLT3MAPK8MAPK9CDK2 | |
| SCHEMBL376245 | 0.83 | IRAK4 (0.59) | IRAK4FLT3MAPK8MAPK9CDK2 | |
| SCHEMBL10239507 | 0.83 | IRAK4 (0.55) | IRAK4FLT3MAPK8MAPK9 | |
| SCHEMBL376677 | 0.81 | IRAK4 (0.78) | IRAK4FLT3MAPK8NRASIRAK1 | |
| SCHEMBL376510 | 0.81 | IRAK4 (0.78) | IRAK4FLT3MAPK8NRASIRAK1 | |
| SCHEMBL3238386 | 0.81 | CDK2 (0.46) | IRAK4FLT3MAPK8MAPK9JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | IRAK4 12/4885FLT3 21/4885MAPK8 241/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | IRAK4 816/4885FLT3 496/4885MAPK8 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.